A/Prof Michael Slancar 39 White Street, Southport, Queensland 4215

Welcome to the webpage for A/Prof Michael Slancar, located at Southport, White Street, 39. A/Prof Michael Slancar is a renowned doctor and establishment in the field of health, specializing in personalized cancer care. He is dedicated to providing world-class treatment to his patients and is committed to staying at the forefront of leading clinical research.

With extensive experience as a medical oncologist, A/Prof Slancar received his specialist training in Europe and completed his training in Sydney, Australia. Prior to joining Icon Cancer Centre Southport, he worked at Royal North Shore Hospital in Sydney. In 1998, he established Gold Coast Oncology, a coordinated cancer care practice in Southport. He also founded Gold Coast Oncology Research Pty Ltd, a private organization focused on international clinical trials.

A/Prof Slancar's clinical expertise covers a wide range of solid tumor malignancies, with a special interest in breast cancer, gynecological malignancies, colorectal cancer, lung cancer, and prostate cancer. His practice offers comprehensive management of any malignancy at any stage, from initial diagnosis to palliative care.

A/Prof Slancar is also highly involved in clinical trials and is recognized internationally as a principal investigator. He actively participates in numerous international studies for the treatment of solid tumors and has access to a wide range of clinical trials for major malignancies. Additionally, he specializes in personalized medicine, collaborating with international groups to provide the best individualized care for cancer patients based on precise tumor profiling.

At present, A/Prof Slancar is involved in several important studies, including a Phase 1 Dose Escalation and Expansion Open-label, Multicenter Study of OP-1250 in Combination with the CDK4/6 Inhibitor Palbociclib for advanced or metastatic HR-positive, HER2-negative Breast Cancer. He is also part of a Phase 2/3 Study of ALX148 in patients with advanced HER2-overexpressing Gastric/Gastroesophageal Junction Adenocarcinoma (ASPEN-06). Additionally, he is conducting a study on Adjuvant Cemiplimab versus Placebo after Surgery and Radiation Therapy in Patients with High Risk Cutaneous Squamous Cell Carcinoma.

When you choose A/Prof Michael Slancar for your cancer care, you can trust that you are receiving exceptional treatment backed by the latest research and personalized care tailored to your specific needs. Contact us today to schedule an appointment and experience the difference of world-class cancer care.